help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Knutsen, R.
Right arrow Articles by Mohan, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Knutsen, R.
Right arrow Articles by Mohan, S.

Endocrinology, Vol 136, 857-865, Copyright © 1995 by Endocrine Society


ARTICLES

Regulation of insulin-like growth factor system components by osteogenic protein-1 in human bone cells

R Knutsen, Y Honda, DD Strong, TK Sampath, DJ Baylink and S Mohan
Department of Medicine, Loma Linda University, California.

Bone morphogenetic proteins (BMPs) have the unique ability to convert mesenchymal cells into matrix-producing osteoblasts. To understand the mechanism(s) by which a BMP produces a multitude of effects on bone cells, we examined the effects of recombinant human osteogenic protein (OP)-1 (referred to as BMP-7) on the insulin-like growth factor (IGF) regulatory system, an important growth factor system in bone. After 48 h of treatment, OP-1 increased the level of IGF-II (3- and 2-fold, respectively, at 100 ng/ml) in the conditioned medium (CM) of SaOS-2 and TE85 human osteosarcoma cells with osteoblastic characteristics, whereas IGF-I levels were low to undetectable in the CM of either cell type. OP-1 treatment had no significant effect on the messenger RNA (mRNA) level for type 1 and type 2 IGF receptors. In TE85 and SaOS-2 cells, 100 ng/ml OP-1 increased the level of IGF binding protein (BP)-3 more than 10-fold, decreased the IGFBP-4 level by 50%, and increased the level of the 29-32.5 kDa IGFBP-5 3-fold in the CM as determined by analysis with Western ligand blot, Western immunoblot, and RIA. The effect of OP-1 on IGFBP production was time and dose dependent. The OP- 1 induced changes in the levels of IGFBPs were associated with decreased IGFBP-3 and -5 protease activity (29% and 71%, respectively) and proportional changes in IGFBP mRNA levels. OP-1 increased the level of IGFBP-3 mRNA (2- and 10-fold, respectively, after 4 and 24 h of treatment at 100 ng/ml) and of IGFBP-5 mRNA (more than 5-fold after 24 h of treatment) but decreased the level of IGFBP-4 mRNA (> 50% after 24 h at 100 ng/ml). OP-1 treatment had no effect on IGFBP-4 protease activity. These results collectively demonstrate that OP-1 can act locally by modulating the IGF regulatory system, suggesting that the mitogenic/differentiative effect of OP-1 on human bone cells may in part be mediated via IGF-II by increasing its secretion, and by regulating the balance between the stimulatory (e.g. IGFBP-5) and inhibitory (e.g. IGFBP-4) classes of IGFBPs both at the level of production (mRNA) and at the level of degradation but not by up- regulating the IGF receptor.


This article has been cited by other articles:


Home page
JBJSHome page
A. Minamide, S. D. Boden, M. Viggeswarapu, G. A. Hair, C. Oliver, and L. Titus
Mechanism of Bone Formation with Gene Transfer of the cDNA Encoding for the Intracellular Protein LMP-1
J. Bone Joint Surg. Am., May 28, 2003; 85(6): 1030 - 1039.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
E. Canalis, A. N. Economides, and E. Gazzerro
Bone Morphogenetic Proteins, Their Antagonists, and the Skeleton
Endocr. Rev., April 1, 2003; 24(2): 218 - 235.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
W. A. Price
Peptide Growth Factors Regulate Insulin-Like Growth Factor Binding Protein Production by Fetal Rat Lung Fibroblasts
Am. J. Respir. Cell Mol. Biol., February 1, 1999; 20(2): 332 - 341.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
X. Qin, D. D. Strong, D. J. Baylink, and S. Mohan
Structure-Function Analysis of the Human Insulin-like Growth Factor Binding Protein-4
J. Biol. Chem., September 4, 1998; 273(36): 23509 - 23516.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
S. Rajaram, D. J. Baylink, and S. Mohan
Insulin-Like Growth Factor-Binding Proteins in Serum and Other Biological Fluids: Regulation and Functions
Endocr. Rev., December 1, 1997; 18(6): 801 - 831.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
L.-C. C. Yeh, M. L. Adamo, M. S. Olson, and J. C. Lee
Osteogenic Protein-1 and Insulin-Like Growth Factor I Synergistically Stimulate Rat Osteoblastic Cell Differentiation and Proliferation
Endocrinology, October 1, 1997; 138(10): 4181 - 4190.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
J. M. Hayden, D. D. Strong, D. J. Baylink, D. R. Powell, T. K. Sampath, and S. Mohan
Osteogenic Protein-1 Stimulates Production of Insulin-Like Growth Factor Binding Protein-3 Nuclear Transcripts in Human Osteosarcoma Cells
Endocrinology, October 1, 1997; 138(10): 4240 - 4247.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1995 by The Endocrine Society